Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 13Breast 3Thoracic 2Sarcoma 2Dermatologic 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Pancreatic Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 22Ipilimumab 17Nivolumab 16pembrolizumab 11Temozolomide 9encorafenib 8dabrafenib 8binimetinib 8Magnetic Resonance Spectroscopy 6trametinib 5Bevacizumab 5CTLA-4 Antigen 4cobimetinib 3Thalidomide 3Radiotherapy 3Paclitaxel 3entrectinib 2cediranib 2Vemurafenib 2Spermine Synthase 2Specimen Handling 2Radiation 2Pemetrexed 2Opdualag 2Drug Therapy 2Carboplatin 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 214-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 2130-nm albumin-bound paclitaxel 2relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × abemaciclib × Dermatologic × Clear all
NCT02308020 2020-12-19

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

Eli Lilly and Company

Phase 2 Completed
162 enrolled 25 charts
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡